

Application for the following position in the EHRA Board:

**Treasurer**



## 1. Your Identity

Title: Prof.Dr.

Family Name(s): Van Gelder

First Name(s): Isabelle Carole

Birth Date: May 16 1959

Institute/Organisation: University Medical Center Groningen

Department: Cardiology

Address: Molenhorn 17

Post Code/Zip: 9797 PV

City: Thesinge

Country: The Netherlands

**EHRA**European Heart  
Rhythm Association

## 2. General Curriculum Vitae (300 words max)

**Actual position:**

- 1996 - **Cardiologist-electrophysiologist**, Staff member Department of Cardiology, University Medical Center Groningen. Chair: Prof.Dr. D.J. Van Veldhuisen
- 2011 - **Full Professor** at University Medical Center Groningen
- 2017 - Adjunct Professor University of Southern Denmark, Odense, Denmark

**Past positions:**

- 2001 - 2016 Chair department electrophysiology/ devices
- 2001 - 2006 Associate Professor University Medical Center Groningen
- 2006 - 2011 Professor at Interuniversity Cardiology Institute Netherlands and University Medical Center Groningen

**Professional training:**

- 1986: **MD**
- 1986 – 1990: Research Fellow Cardiology, University Medical Center Groningen
- 1990 – 1995: Cardiology training, University Medical Center Groningen
- 1991: **PhD Thesis: Management of chronic atrial fibrillation in the nineties**
- 1995: **Cardiologist**

**Fellowships:**

- 1993 – 1995 **Fellow electrophysiology**
- 1995 – 1996 **Fellow post doc molecular biology** Interuniversity Cardiology Institute the Netherlands (ICIN): University of Cologne Prof.Dr.M.Böhm (Germany)
- 1996 – 1999 **Fellow post-doc Netherlands Heart Foundation** (dr.E.Dekker grant): new therapeutic strategies for atrial fibrillation (RACE study)

**Awards:**

- 2016: **Bert Talen** lecture and medal for atrial fibrillation research. Netherlands Heart Rhythm Association
- 2019: **ESC 2019 René Laënnec lecture and ESC silver medal** for work in clinical Cardiology.

**Scientific activities:**

- > €20 million research grants for atrial fibrillation research
- > 300 peer reviewed papers
- Promotor > 25 PhD students.
- PI > 30 trials including the RACE trials, STEER-AF and EHRA-PATHS
- Steering committee member > 25 international trials including EAST, AXAFA, ASSERT and APAF-CRT
- Executive committee member OCEANIC-AF trial (Factor-XI-inhibitor for stroke prevention)
- DSMB member FRAIL-AF (apixaban versus VKA in elderly) and Pulmonary Vein Isolation versus SHAM-PVI for symptomatic relief.
- Task Force member ESC AF 2010, 2012 and 2020 guidelines
- Associate Editor of Europace (since 2007) and Heart (since 2019).

My research focuses on understanding the susceptibility to atrial fibrillation and its adverse outcomes. It explores novel management strategies to prevent adverse outcomes with a focus on cardiovascular risk

**ESC**European Society  
of Cardiology



### **3. Describe previous experience(s) within EHRA, ESC or your National Cardiac Society**

Activities for EHRA:

- Education Committee 2007-2009 Co-chair; 2015-2017 Member
- Scientific Programme Committee Co-chair 2011-2013, Member 2017-2020, Chair 2020-2022
- Scientific Initiative Committee Member 2011-2013,
- Nominating Committee Member 2015-2017
- EHRA membership pillar Chair 2017-2020
- EHRA board Member 2017-2022

Executive board member of ESC stroke council (2016-2020, secretary/treasurer).

Member of the Netherlands Heart Rhythm Association since 1997

Secretary of the Netherlands Heart Rhythm Association 2007-2009.





#### 4. Why are you motivated to join the EHRA Executive Board (150 words max)?

For several reasons I am very enthusiastic and motivated to continue my work within EHRA, since it is my belief that electrophysiologists need a professional and scientific organization to educate, to certify young physicians, to make care uniform throughout Europe, to encourage and support women to become electrophysiologists and build a career, and to encourage exchange of ideas.

My aims for this term would be:

1. To **further increase the visibility** of cardiac electrophysiology as key part of cardiology and of EHRA as the global world player in this arena.
2. To improve **disparities** in arrhythmic therapies across all ESC countries and around the world. I hope to contribute to **equality** between sex, age, socio-economic classes and countries.
3. To continue my contribution to improve disparities between female and male electrophysiologists/ cardiologists (in training) and continue my role as role model: improving opportunities and visibility for women within EHRA and within the ESC.
4. To continue my work on (independent) **education**, including the EHRA congress, other EHRA educational activities, and my work as co-PI of STEER-AF.
5. To improve and increase high quality **research** activities within EHRA (like in EHRA-PATHS)
6. To contribute to optimal **relationships with the ESC, other ESC affiliated councils and associations, and with sister societies**
7. To contribute to optimal and **transparent relationships with companies**
8. To continue to be a member of the **'EHRA world' and exchange ideas with my EHRA friends**





## 5. How will you combine your EHRA position with your daily clinical/research workload?

Please note that we expect you to be:

- Active career at the time of taking office
- In clinical practice (for at least 30%) at the time of application

---

During my career, I have learnt to combine clinical work, research and activities for a scientific association such as EHRA. I have gathered experience on how to cope with these tasks throughout the day. The last two years being chair of the scientific programme committee was busy but I could manage and delivered in time. For the coming years I will continue my clinical work for at least 50%. Further, I will continue my research and I hope to stay involved in EHRA, preferably as treasurer and member of the executive board.

## 6. Please list your conflicts of interest

- Direct personal payments (speaker fees, honoraria, advisory board fees, consultancy, investigator...)
  - Company (one company): **none**
  - Product or therapeutic area:
  - <10 K€/year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year
- Payments to your institution (speaker fees, honoraria, advisory board fees, consultancy, activities executed by your department for the sponsor or investigator initiated and funded by an unconditional grant from the sponsor...)
  - Company (one company): BMS, Pfizer, Daiichi, Medtronic, Bayer
  - Product or therapeutic area: AF therapies and stroke prevention
  - **<10 K€/ year**
- Receipts of royalties for intellectual property
  - Company (one company): **none**
  - Product or therapeutic area:
  - <10 K€/ year ☐ 10-50 K€/year ☐ 50-100 K€/year ☐ >100 >K€/year





**Add as many as necessary**

**Position of influence declaration:**

- Direct substantial shareholding or direct financial interest in healthcare, media, education companies or companies in relationship (suppliers or in competition with ESC or in contradiction with ESC mission)
- Employment in healthcare institution (part time or full time)
- Membership or affiliation to political/pressure group associations related to the field of cardiology
- Any potential interest related to the position applied for
- Nothing to declare
- More info at <https://www.escardio.org/The-ESC/About/Policies/esc-declaration-and-management-of-conflict-of-interest-policy>

